Skip to main content
Top
Published in: Cardiology and Therapy 2/2022

Open Access 15-04-2022 | Stroke | Original Research

Thrombotic and Cardiovascular Events and Treatment Patterns Among Patients Hospitalized with COVID-19 in Japan: An Analysis of a Nationwide Medical Claims Database

Authors: Naoki Terasaka, Yukako Matsuo, Hirohide Kataoka, Yasuhiko Miyata, Yoshio Anazawa

Published in: Cardiology and Therapy | Issue 2/2022

Login to get access

Abstract

Introduction

Limited data are available regarding the prevalence of thrombotic/cardiovascular disease and treatment patterns for patients with coronavirus disease 2019 (COVID-19) in Japan. In this study we describe patients hospitalized for COVID-19 in Japan.

Methods

This retrospective database study analyzed the Japan Medical Data Vision database (416 acute care hospitals) for patients hospitalized for COVID-19 during the identification period from 1 January 1 to 30 September 2020.

Results

Among 9282 eligible patients, 832 (9%) had developed thrombotic disease including myocardial infarction, ischemic stroke, deep vein thromboembolism and pulmonary embolism. Intriguingly, 171(1.8%) had two thrombotic events and 25 (0.3%) had three or four thrombotic events at the same time. The data also showed that arterial thrombotic events accounted for 77% of total thrombotic events. Anticoagulant and/or antiplatelet medication was provided to 3312 patients. Even with antithrombotic medication, 21.2% of patients suffered from thrombotic diseases.

Conclusions

Patients with COVID-19 could experience thrombotic complications in every blood vessel. Further optimization of medication is crucial for preventing thrombotic complications and improving prognosis.
Literature
1.
go back to reference Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef
2.
go back to reference Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.CrossRef Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.CrossRef
3.
go back to reference Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–55.CrossRef Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–55.CrossRef
4.
go back to reference Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–9.CrossRef Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–9.CrossRef
5.
go back to reference Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50.CrossRef Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50.CrossRef
6.
go back to reference Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60.CrossRef Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60.CrossRef
7.
go back to reference Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51(7):2002–11.CrossRef Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51(7):2002–11.CrossRef
9.
go back to reference Chen L, Ionescu-Ittu R, Romdhani H, et al. Disease management and outcomes in patients hospitalized for acute heart failure in Japan. Cardiol Ther. 2021;10:211–28.CrossRef Chen L, Ionescu-Ittu R, Romdhani H, et al. Disease management and outcomes in patients hospitalized for acute heart failure in Japan. Cardiol Ther. 2021;10:211–28.CrossRef
10.
go back to reference Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27(10):476–82.CrossRef Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27(10):476–82.CrossRef
11.
go back to reference Horiuchi H, Morishita E, Urano T, Yokoyama K. COVID-19-related thrombosis in Japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. 2021;28(4):406–16.CrossRef Horiuchi H, Morishita E, Urano T, Yokoyama K. COVID-19-related thrombosis in Japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. 2021;28(4):406–16.CrossRef
12.
go back to reference Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–46.CrossRef Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–46.CrossRef
13.
go back to reference Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost. 2011;9(10):1877–82.CrossRef Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost. 2011;9(10):1877–82.CrossRef
14.
go back to reference Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222–31.CrossRef Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222–31.CrossRef
15.
go back to reference Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398:599–607.CrossRef Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398:599–607.CrossRef
16.
go back to reference Matsumoto S, Kuroda S, Sano T, et al. Clinical and biomarker profiles and prognosis of elderly patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases and/or risk factors. Circ J. 2021;85(6):921–8.CrossRef Matsumoto S, Kuroda S, Sano T, et al. Clinical and biomarker profiles and prognosis of elderly patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases and/or risk factors. Circ J. 2021;85(6):921–8.CrossRef
17.
go back to reference Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12(6):629.CrossRef Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12(6):629.CrossRef
18.
go back to reference Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.CrossRef Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.CrossRef
19.
go back to reference Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–63.CrossRef Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–63.CrossRef
20.
go back to reference Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103.CrossRef Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103.CrossRef
21.
go back to reference Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295(9):1050–7.CrossRef Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295(9):1050–7.CrossRef
22.
go back to reference Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588(7836):146–50.CrossRef Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588(7836):146–50.CrossRef
23.
go back to reference Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.CrossRef Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.CrossRef
Metadata
Title
Thrombotic and Cardiovascular Events and Treatment Patterns Among Patients Hospitalized with COVID-19 in Japan: An Analysis of a Nationwide Medical Claims Database
Authors
Naoki Terasaka
Yukako Matsuo
Hirohide Kataoka
Yasuhiko Miyata
Yoshio Anazawa
Publication date
15-04-2022
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2022
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-022-00263-9

Other articles of this Issue 2/2022

Cardiology and Therapy 2/2022 Go to the issue